Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis

Abstract

This systematic review and meta-analysis is the first to evaluate the evidence for an association between metformin use and cancer outcomes in patients undergoing treatment with curative intent for individual cancer types. Our findings suggest that adjuvant metformin could have beneficial effects, particularly on cancer outcomes in colorectal and prostate cancer. Randomised trials are warranted.

Metformin associated inflammation levels regulation in type 2 diabetes mellitus-tuberculosis coinfection patients – A case report

“…MET is known affecting inflammation 38. mediators, both pro-inflammation, such IFN-γ, IL-β and also anti-inflammation such IL-10 39. [8][9][10] . Interferon (IFN)-γ is a potent cytokine that indicates antimicrobial effect and also 40. modulates the production or activities of several cytokines and chemokines [11][12][13] …”

Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors

“…An increasing number of studies have associated MET treatment with a decrease in cancer risk. Moreover, MET has also been associated with improved outcomes in cancer patients [12][13][14][15][16]. In a recently published systematic review and metaanalysis, Coyle et al [16] enrolled 24,178 patients affected by colorectal, prostate, breast and urothelial cancer.…”

“…Moreover, MET has also been associated with improved outcomes in cancer patients [12][13][14][15][16]. In a recently published systematic review and metaanalysis, Coyle et al [16] enrolled 24,178 patients affected by colorectal, prostate, breast and urothelial cancer. The authors showed that MET use was associated with a significant benefit in all the outcomes, in particular in early-stage colorectal cancer and prostate cancer, suggesting its use as an adjuvant agent [16].…”

Biguanides enhance antifungal activity against Candida glabrata

“…Recently, there has been interest surrounding the expanded therapeutic potential of metformin to include treatment and prevention of various types of cancer. Numerous clinical and preclinical studies suggest that metformin has anticancer properties, with a role in cancer stem cell suppression, epithelial-to-mesenchymal transition inhibition, and interference in cancer cell metabolism [23–25]. In addition, metformin is an effective adjuvant to several chemotherapy agents.…”

“…In addition, metformin is an effective adjuvant to several chemotherapy agents. A meta-analysis of clinical trials using metformin as an adjuvant demonstrated improved survival outcomes as compared with standard of care, especially in colorectal and prostate cancer patients [25]. …”